Oncology & Immunology Unit, Calvary Mater Newcastle Hospital, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.
Melanoma Res. 2012 Jun;22(3):244-51. doi: 10.1097/CMR.0b013e328353eff2.
Relatively little attention has been paid to the activity of selective BRAF inhibitors in the induction of apoptosis in melanoma, particularly in vivo. In the present study, we have isolated cultures from biopsies taken from four patients before and during the treatment of their melanoma. We report that the cell lines taken during treatment show varying degrees of upregulation of the proapoptotic BH3 protein Bim and its splice forms, downregulation of Mcl-1, and upregulation of the splicing factor SRp55 as reported in previous in-vitro studies. There was also evidence of ongoing apoptotic signaling despite the continued growth of the cultures. The cultures established during the treatment were largely resistant to the selective BRAF inhibitor PLX4720, consistent with the acquired resistance of melanoma in the treated patients. These results provide further insights into the mechanism of action of these agents against melanoma.
相对较少关注选择性 BRAF 抑制剂在黑色素瘤细胞凋亡诱导中的作用,特别是在体内。在本研究中,我们从四名患者在接受黑色素瘤治疗前后的活检中分离培养物。我们报告说,治疗期间采集的细胞系表现出不同程度的促凋亡 BH3 蛋白 Bim 及其剪接形式的上调、Mcl-1 的下调以及先前在体外研究中报道的剪接因子 SRp55 的上调。尽管培养物仍在继续生长,但仍有证据表明凋亡信号仍在继续。在治疗期间建立的培养物对选择性 BRAF 抑制剂 PLX4720 具有很强的抗性,这与接受治疗的患者中黑色素瘤的获得性耐药一致。这些结果为这些药物针对黑色素瘤的作用机制提供了进一步的见解。